Targeting IL-33 in autoimmunity and inflammation

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 1, 2015, Pages 24-31

  Theoharides, Theoharis C ^a,b,c   Petra, Anastasia I ^a   Taracanova, Alexandra ^a,b   Panagiotidou, Smaro ^a   Conti, Pio ^d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR 4; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; INFLAMMATION; MAST CELL; MULTIPLE SCLEROSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; GENE EXPRESSION REGULATION; HUMANS; HYPERSENSITIVITY; INFLAMMATION; INTERLEUKINS; MAST CELLS; RECEPTORS, INTERLEUKIN;

EID: 84935099110     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.222505     Document Type: Review

References (164)

1. Abraham SN and St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10:440-452.
2. Alase A, Seltmann J, Werfel T, and Wittmann M (2012) Interleukin-33 modulates the expression of human β-defensin 2 in human primary keratinocytes and may influence the susceptibility to bacterial superinfection in acute atopic dermatitis. Br J Dermatol 167:1386-1389.
3. Allakhverdi Z, Smith DE, Comeau MR, and Delespesse G (2007) Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 179:2051-2054.
4. Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M, Kalogeromitros D, and Theoharides TC (2011) Brief report: "allergic symptoms" in children with Autism Spectrum Disorders. More than meets the eye? J Autism Dev Disord 41:1579-1585.
5. Arend WP, Palmer G, and Gabay C (2008) IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223:20-38.
6. Ashwood P and Van de Water J (2004) A review of autism and the immune response. Clin Dev Immunol 11:165-174.
7. Askenase PW (2003) Mast cells and the mediation of T-cell recruitment in arthritis. N Engl J Med 349:1294.
8. Awada A, Nicaise C, Ena S, Schandéné L, Rasschaert J, Popescu I, Gangji V, and Soyfoo MS (2014) Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome. Ann Rheum Dis 73:1259-1263.
9. Balato A, Lembo S, Mattii M, Schiattarella M, Marino R, De Paulis A, Balato N, and Ayala F (2012) IL-33 is secreted by psoriatic keratinocytes and induces proinflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 21:892-894.
10. Barbour M, Allan D, Xu H, Pei C, Chen M, Niedbala W, Fukada SY, Besnard AG, Alves-Filho JC, Tong X, et al. (2014) IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol 44:3320-3329.
11. Beltrán CJ, Núñez LE, Díaz-Jiménez D, Farfan N, Candia E, Heine C, López F, González MJ, Quera R, and Hermoso MA (2010) Characterization of the novel ST2/ IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16: 1097-1107.
12. Blank U and Rivera J (2004) The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 25:266-273.
13. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL, and Theoharides TC (2005) Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 174:7665-7675.
14. Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tete S, Ciampoli C, Conti F, Cerulli G, Caraffa A, Antinolfi P, et al. (2009) The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator. J Biol Regul Homeost Agents 23: 11-14.
15. Cayrol C and Girard JP (2009) The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 106:9021-9026.
16. Celik HT, Abusoglu S, Burnik SF, Sezer S, Serdar MA, Ercan M, Uguz N, Avcikucuk M, Ceylan B, and Yildirimkaya M (2013) Increased serum interleukin-33 levels in patients with Graves' disease. Endocr Regul 47:57-64.
17. Cevikbas F and Steinhoff M (2012) IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol 132:1326-1329.
18. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, and Kastelein RA (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551-2555.
19. Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, and Massa PT (2012) Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 142:308-319.
20. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, Kou Y, Liu L, Fromer M, Walker S, et al. (2014) Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515:209-215.
21. Dinarello CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20 (5, Suppl 27)S1-S13.
22. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550.
23. Dinarello CA, Simon A, and van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11: 633-652.
24. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Dobner P, and Theoharides TC (2006) Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 103:7759-7764.
25. Drube S, Heink S, Walter S, Löhn T, Grusser M, Gerbaulet A, Berod L, Schons J, Dudeck A, Freitag J, et al. (2010) The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 115:3899-3906.
26. Drube S, Schmitz F, Göpfert C, Weber F, and Kamradt T (2012) C-Kit controls IL-1 β-induced effector functions in HMC-cells. Eur J Pharmacol 675:57-62.
27. Duan L, Chen J, Gong F, and Shi G (2013) The role of IL-33 in rheumatic diseases. Clin Dev Immunol 2013:924363.
28. Eiwegger T and Akdis CA (2011) IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma. Eur J Immunol 41:1535-1538.
29. Enoksson M, Lyberg K, Möller-Westerberg C, Fallon PG, Nilsson G, and Lunderius-Andersson C (2011) Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 186:2523-2528.
30. Enoksson M, Möller-Westerberg C, Wicher G, Fallon PG, Forsberg-Nilsson K, Lunderius-Andersson C, and Nilsson G (2013) Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood 121:530-536.
31. Franchi L and Núñez G (2012) Immunology. Orchestrating inflammasomes. Science 337:1299-1300.
32. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, et al. (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42:1118-1125.
33. Fux M, Pecaric-Petkovic T, Odermatt A, Hausmann OV, Lorentz A, Bischoff SC, Virchow JC, and Dahinden CA (2014) IL-33 is a mediator rather than a trigger of the acute allergic response in humans. Allergy 69:216-222.
34. Galli SJ, Tsai M, Wershil BK, Tam S-Y, and Costa JJ (1995) Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int Arch Allergy Immunol 107:51-53.
35. Galli SJ, Nakae S, and Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6:135-142.
36. Garlanda C, Dinarello CA, and Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39:1003-1018.
37. Griffin WS (2013) Neuroinflammatory cytokine signaling and Alzheimer's disease. N Engl J Med 368:770-771.
38. Griffin WS and Barger SW (2010) Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis. US Neurol 6:19-27.
39. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, West AB, and Arking DE (2014) Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun 5:5748.
40. Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ, Kawagoe T, Imoto Y, Fujieda S, Yasuda M, Hisa Y, Akira S, et al. (2012) A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 130:184-194, e11.
41. Hayakawa H, Hayakawa M, Kume A, and Tominaga S (2007) Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282: 26369-26380.
42. Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Sakashita M, Yamada T, Fujieda S, Tanaka S, Doi S, et al. (2012) Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet 44:1222-1226.
43. Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, Okayama Y, Akira S, Saito H, Galli SJ, et al. (2007) IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 82:1481-1490.
44. Hox V, Vanoirbeek JA, Alpizar YA, Voedisch S, Callebaut I, Bobic S, Sharify A, De Vooght V, Van Gerven L, Devos F, et al. (2013) Crucial role of transient receptor potential ankyrin 1 and mast cells in induction of nonallergic airway hyperreactivity in mice. Am J Respir Crit Care Med 187:486-493.
45. Hsu CL, Neilsen CV, and Bryce PJ (2010) IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 5:e11944.
46. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, Graham GJ, Liew FY, Miller AM, and McInnes IB (2011) IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 41:2229-2237.
47. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, Saito H, Galli SJ, and Nakae S (2007) IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 87:971-978.
48. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, Stessman HA, Witherspoon KT, Vives L, Patterson KE, et al. (2014) The contribution of de novo coding mutations to autism spectrum disorder. Nature 515:216-221.
49. Jafarzadeh A, Mohammadi-Kordkhayli M, Ahangar-Parvin R, Azizi V, Khoramdel-Azad H, Shamsizadeh A, Ayoobi A, Nemati M, Hassan ZM, Moazeni SM, et al. (2014) Ginger extracts influence the expression of IL-27 and IL-33 in the central nervous system in experimental autoimmune encephalomyelitis and ameliorates the clinical symptoms of disease. J Neuroimmunol 276:80-88.
50. Jäger AK and Saaby L (2011) Flavonoids and the CNS. Molecules 16:1471-1485.
51. Jang S, Kelley KW, and Johnson RW (2008) Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 105:7534-7539.
52. Jones QR, Warford J, Rupasinghe HP, and Robertson GS (2012) Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol Sci 33:602-610.
53. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, et al.; International IBD Genetics Consortium (IIBDGC) (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119-124.
54. Jung MY, Smrz D, Desai A, Bandara G, Ito T, Iwaki S, Kang JH, Andrade MV, Hilderbrand SC, Brown JM, et al. (2013) IL-33 induces a hyporesponsive phenotype in human and mouse mast cells. J Immunol 190:531-538.
55. Kaieda S, Wang JX, Shnayder R, Fishgal N, Hei H, Lee RT, Stevens RL, and Nigrovic PA (2012) Interleukin-33 primes mast cells for activation by IgG immune complexes. PLoS ONE 7:e47252.
56. Kakkar R and Lee RT (2008) The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7:827-840.
57. Kamijo S, Takeda H, Tokura T, Suzuki M, Inui K, Hara M, Matsuda H, Matsuda A, Oboki K, Ohno T, et al. (2013) IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol 190:4489-4499.
58. Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, Boucher W, Athanassiou A, and Theoharides TC (2003) IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 171: 4830-4836.
59. Kandere-Grzybowska K, Kempuraj D, Cao J, Cetrulo CL, and Theoharides TC (2006) Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol 148:208-215.
60. Karagkouni A, Alevizos M, and Theoharides TC (2013) Effect of stress on brain inflammation and multiple sclerosis. Autoimmun Rev 12:947-953.
61. Kassiotis G and Kollias G (2001) Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193:427-434.
62. Kaur D, Doe C, Woodman L, Wan WY, Sutcliffe A, Hollins F, and Brightling C (2012) Mast cell-airway smooth muscle crosstalk: the role of thymic stromal lymphopoietin. Chest 142:76-85.
63. Kaur D, Gomez E, Doe C, Berair R, Woodman L, Saunders R, Hollins F, Rose FR, Amrani Y, May R, et al. (2015) IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. Allergy 70:556-567.
64. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, and Theoharides TC (2005) Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 145:934-944.
65. Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, House M, Wolfberg A, and Theoharides TC (2008) Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. Br J Pharmacol 155:1076-1084.
66. Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E, and Zaheer A (2013) Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. J Neuroimmune Pharmacol 8:643-650.
67. Kenna TJ and Brown MA (2013) The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol 9:375-379.
68. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, and Nagai H (2000) Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 30:501-508.
69. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, and Kita H (2011) The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 186:4375-4387.
70. Kozauer N and Katz R (2013) Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 368:1169-1171.
71. Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, et al. (2013) Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 27:655-660.
72. Kunder CA, St John AL, Li G, Leong KW, Berwin B, Staats HF, and Abraham SN (2009) Mast cell-derived particles deliver peripheral signals to remote lymph nodes. J Exp Med 206:2455-2467.
73. Lee HY, Rhee CK, Kang JY, Byun JH, Choi JY, Kim SJ, Kim YK, Kwon SS, and Lee SY (2014) Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma. Exp Lung Res 40:66-76.
74. Lefrançais E and Cayrol C (2012) Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw 23: 120-127.
75. Lefrançais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP, and Cayrol C (2012) IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA 109:1673-1678.
76. Lefrancais E, Duval A, Mirey E, Roga S, Espinosa E, Cayrol C, and Girard JP (2014) Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A 111:15502-15507.
77. Liew FY, Pitman NI, and McInnes IB (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10:103-110.
78. Lin J, Zhao GQ, Wang Q, Xu Q, Che CY, Hu LT, Jiang N, Wang Q, and Zhang LL (2013) Regulation of interleukin 33/ST2 signaling of human corneal epithelium in allergic diseases. Int J Ophthalmol 6:23-29.
79. Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W, and Qin Q (2014) IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun 453:486-492.
80. Llop-Guevara A, Chu DK, Walker TD, Goncharova S, Fattouh R, Silver JS, Moore CL, Xie JL, O'Byrne PM, Coyle AJ, et al. (2014) A GM-CSF/IL-33 pathway facilitates allergic airway responses to sub-threshold house dust mite exposure. PLoS ONE 9:e88714.
81. Lloyd CM (2010) IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol 22:800-806.
82. Löhning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A, and Kamradt T (1998) T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 95:6930-6935.
83. Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, Bourne P, McClanahan TK, Pflanz S, and de Waal Malefyt R (2011) Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 23:307-315.
84. Lukens JR, Gross JM, and Kanneganti TD (2012) IL-1 family cytokines trigger sterile inflammatory disease. Front Immunol 3:315.
85. Lunderius-Andersson C, Enoksson M, and Nilsson G (2012) Mast Cells Respond to Cell Injury through the Recognition of IL-33. Front Immunol 3:82.
86. Matsuda H, Kannan Y, Ushio H, Kiso Y, Kanemoto T, Suzuki H, and Kitamura Y (1991) Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J Exp Med 174:7-14.
87. McLean MH, Neurath MF, and Durum SK (2014) Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy? Inflamm Bowel Dis 20:389-397.
88. Middleton E, Jr, Kandaswami C, and Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751.
89. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, and Lukic ML (2012) IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 52:89-99.
90. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, and Cookson WO; GABRIEL Consortium (2010) A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 363:1211-1221.
91. Moon H, Choi HH, Lee JY, Moon HJ, Sim SS, and Kim CJ (2008) Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs. Arch Pharm Res 31:771-778.
92. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, and Gabay C (2007) Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40:216-225.
93. Moussion C, Ortega N, and Girard JP (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 3:e3331.
94. Nabe T (2014) Interleukin (IL)-33: new therapeutic target for atopic diseases. J Pharmacol Sci 126:85-91.
95. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, and Galli SJ (2005) Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci USA 102:6467-6472.
96. Nakae S, Suto H, Berry GJ, and Galli SJ (2007) Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 109:3640-3648.
97. Nicoletti M, Maccauro G, Tripodi D, Saggini A, Potalivo G, Castellani M, Conti F, Rosati M, Toniato E, Caraffa A, et al. (2012) Impact of IL-33 on PGD2 generation by activated human cord blood-derived mast cell: lack of effect on tryptase release. Euro J Inflamm 10:473-482.
98. Nile CJ, Barksby E, Jitprasertwong P, Preshaw PM, and Taylor JJ (2010) Expression and regulation of interleukin-33 in human monocytes. Immunology 130: 172-180.
99. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, Nambu A, Abe T, Kiyonari H, Matsumoto K, et al. (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 107:18581-18586.
100. Oboki K, Nakae S, Matsumoto K, and Saito H (2011) IL-33 and Airway Inflammation. Allergy Asthma Immunol Res 3:81-88.
101. Olszewski MB, Groot AJ, Dastych J, and Knol EF (2007) TNF trafficking to human mast cell granules: mature chain-dependent endocytosis. J Immunol 178: 5701-5709.
102. Park HH, Lee S, Son HY, Park SB, Kim MS, Choi EJ, Singh TS, Ha JH, Lee MG, Kim JE, et al. (2008) Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Arch Pharm Res 31:1303-1311.
103. Pei C, Barbour M, Fairlie-Clarke KJ, Allan D, Mu R, and Jiang HR (2014) Emerging role of interleukin-33 in autoimmune diseases. Immunology 141:9-17.
104. Pomeshchik Y, Kidin I, Korhonen P, Savchenko E, Jaronen M, Lehtonen S, Wojciechowski S, Kanninen K, Koistinaho J, and Malm T (2015) Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav Immun 44:68-81.
105. Pushparaj PN, Tay HK, H'ng SC, Pitman N, Xu D, McKenzie A, Liew FY, and Melendez AJ (2009) The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 106:9773-9778.
106. Qiu C, Li Y, Li M, Li M, Liu X, McSharry C, and Xu D (2013) Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice. Immunology 138: 76-82.
107. Raeiszadeh JS, Mahesh PA, Jayaraj BS, Madhunapantula SR, Holla AD, Vishweswaraiah S, and Ramachandra NB (2014) Serum levels of IL-10, IL-17F and IL-33 in patients with asthma: a case-control study. J Asthma 51:1004-1013.
108. Rottem M and Mekori YA (2005) Mast cells and autoimmunity. Autoimmun Rev 4:21-27.
109. Rubio-Perez JM and Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer's disease, role of cytokines. Scientific World Journal 2012:756357.
110. Rüger K, Ottenlinger F, Schröder M, Zivkovic A, Stark H, Pfeilschifter JM, and Radeke HH (2014) Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells. Scand J Immunol 80:398-407.
111. Sabatino G, Nicoletti M, Neri G, Saggini A, Rosati M, Conti F, Cianchetti E, Toniato E, Fulcheri M, Caraffa A, et al. (2012) Impact of IL -9 and IL-33 in mast cells. J Biol Regul Homeost Agents 26:577-586.
112. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, Huang LC, Johnson D, Scanlon ST, McKenzie AN, et al. (2013) A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 210: 2939-2950.
113. Salmond RJ, Mirchandani AS, Besnard AG, Bain CC, Thomson NC, and Liew FY (2012) IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J Allergy Clin Immunol 130:1159-1166, e6.
114. Saluja R, Hawro T, Eberle J, Church MK, and Maurer M (2014) Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways. J Biol Regul Homeost Agents 28: 575-585.
115. Saluja R, Ketelaar ME, Hawro T, Church MK, Maurer M, and Nawijn MC (2015) The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol Immunol 63:80-85.
116. Savinko T, Matikainen S, Saarialho-Kere U, Lehto M, Wang G, Lehtimäki S, Karisola P, Reunala T, Wolff H, Lauerma A, et al. (2012) IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 132:1392-1400.
117. Savinko T, Karisola P, Lehtimäki S, Lappeteläinen AM, Haapakoski R, Wolff H, Lauerma A, and Alenius H (2013) ST2 regulates allergic airway inflammation and T-cell polarization in epicutaneously sensitized mice. J Invest Dermatol 133: 2522-2529.
118. Schroder K, Zhou R, and Tschopp J (2010) The NLRP3 inflammasome: a sensor for metabolic danger? Science 327:296-300.
119. Seltmann J, Werfel T, and Wittmann M (2013) Evidence for a regulatory loop between IFN-g and IL-33 in skin inflammation. Exp Dermatol 22:102-107.
120. Silver MR, Margulis A, Wood N, Goldman SJ, Kasaian M, and Chaudhary D (2010) IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 59:207-218.
121. Sismanopoulos N, Delivanis DA, Alysandratos KD, Angelidou A, Therianou A, Kalogeromitros D, and Theoharides TC (2012) Mast cells in allergic and inflammatory diseases. Curr Pharm Des 18:2261-2277.
122. Sjoberg LC, Gregory JA, Dahlen SE, Nilsson GP, and Adner M (2015) Interleukin-33 exacerbates allergic bronchoconstriction in the mice via activation of mast cells Allergy 70:514-521.
123. Skaper SD, Facci L, and Giusti P (2014) Mast cells, glia and neuroinflammation: partners in crime? Immunology 141:314-327.
124. Solanki I, Parihar P, Mansuri ML, and Parihar MS (2015) Flavonoid-based therapies in the early management of neurodegenerative diseases. Adv Nutr 6:64-72.
125. Sternberg Z, Chadha K, Lieberman A, Hojnacki D, Drake A, Zamboni P, Rocco P, Grazioli E, Weinstock-Guttman B, and Munschauer F (2008) Quercetin and interferon-beta modulate immune response (s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol 205:142-147.
126. Sternberg Z, Chadha K, Lieberman A, Drake A, Hojnacki D, Weinstock-Guttman B, and Munschauer F (2009) Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta. J Neuroinflammation 6:28.
127. Subramanian H, Gupta K, Lee D, Bayir AK, Ahn H, and Ali H (2013) β-Defensins activate human mast cells via Mas-related gene X2. J Immunol 191:345-352.
128. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St Clair J, and Shi GP (2007) Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13:719-724.
129. Suurmond J, Dorjée AL, Boon MR, Knol EF, Huizinga TW, Toes RE, and Schuerwegh AJ (2011) Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 13:R150.
130. Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K, Yoshihara Y, Omata K, Matsumoto K, Tsuchiya KJ, et al. (2013) Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 70:49-58.
131. Tamagawa-Mineoka R, Okuzawa Y, Masuda K, and Katoh N (2014) Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol 70: 882-888.
132. Tare N, Li H, Morschauser A, Cote-Sierra J, Ju G, Renzetti L, and Lin TA (2010) KU812 cells provide a novel in vitro model of the human IL-33/ST2L axis: functional responses and identification of signaling pathways. Exp Cell Res 316: 2527-2537.
133. Theoharides TC (2009) Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol 22:859-865.
134. Theoharides TC (2013) Is a subtype of autism an allergy of the brain? Clin Ther 35: 584-591.
135. Theoharides TC and Cochrane DE (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 146:1-12.
136. Theoharides TC and Zhang B (2011) Neuro-inflammation, blood-brain barrier, seizures and autism. J Neuroinflammation 8:168.
137. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, and Conti P (2004) Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 25:563-568.
138. Theoharides TC, Kempuraj D, Tagen M, Conti P, and Kalogeromitros D (2007) Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217:65-78.
139. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, et al. (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107:4448-4453.
140. Theoharides TC, Sismanopoulos N, Delivanis DA, Zhang B, Hatziagelaki EE, and Kalogeromitros D (2011) Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. Trends Pharmacol Sci 32:534-542.
141. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng Z, Miniati A, et al. (2012a) Mast cells and inflammation. Biochim Biophys Acta 1822:21-33.
142. Theoharides TC, Enakuaa S, Sismanopoulos N, Asadi S, Papadimas EC, Angelidou A, and Alysandratos KD (2012b) Contribution of stress to asthma worsening through mast cell activation. Ann Allergy Asthma Immunol 109:14-19.
143. Theoharides TC, Valent P, and Akin C (2015) Mast cells, mastocytosis and related diseases. New Engl J Med, in press.
144. Traister RS, Uvalle CE, Hawkins GA, Meyers DA, Bleecker ER, and Wenzel SE (2015) Phenotypic and genotypic association of epithelial IL1RL1 to human T2-like asthma. J Allergy Clin Immunol 135:92-99.
145. Tung HY, Plunkett B, Huang SK, and Zhou Y (2014) Murine mast cells secrete and respond to interleukin-33. J Interferon Cytokine Res 34:141-147.
146. Vasiadi M, Therianou A, Sideri K, Smyrnioti M, Sismanopoulos N, Delivanis DA, Asadi S, Katsarou-Katsari A, Petrakopoulou T, Theoharides A, et al. (2012) Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis. J Allergy Clin Immunol 129:1410-1413.
147. Vasiadi M, Mondolfi AP, Alysandratos K-D, Therianou A, Katsarou-Katsari A, Petrakopoulou T, Theoharidis A, Miniati A, and Theoharides TC (2013) Neurotensin serum levels and skin gene expression are increased in atopic dermatitis. Br J Dermatol 169:695-699.
148. Villarreal DO and Weiner DB (2014) Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol 28:102-106.
149. Villarreal DO and Weiner DB (2015) IL-33 isoforms: their future as vaccine adjuvants? Expert Rev Vaccines 14:489-492.
150. Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, and Weiner DB (2014) Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 74:1789-1800.
151. Walle T (2007) Methylation of dietary flavones greatly improves their hepatic metabolic stability and intestinal absorption. Mol Pharm 4:826-832.
152. Wang S, Ding L, Liu SS, Wang C, Leng RX, Chen GM, Fan YG, Pan HF, and Ye DQ (2012) IL-33: a potential therapeutic target in autoimmune diseases. J Investig Med 60:1151-1156.
153. Wei G, Hwang L, and Tsai C (2014) Absolute bioavailability, pharmacokinetics and excretion of 5,7,30,40 -tetramethoxyflavone in rats. J Functional Foods 7:136-141.
154. Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, and Theoharides T (2012) Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PloS One 7:e33805.
155. Weng Z, Patel A, Panagiotidou S, and Theoharides TC (2014a) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 14:01574-01577.
156. Weng Z, Patel AB, Vasiadi M, Therianou A, and Theoharides TC (2014b) Luteolin inhibits human keratinocyte activation and decreases NF-κB induction that is increased in psoriatic skin. PLoS ONE 9:e90739.
157. Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, and Zaheer A (2014) Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis 40:297-308.
158. Yu SL, Wong CK, and Tam LS (2013) The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus. Expert Rev Clin Immunol 9:739-749.
159. Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ, and Hu WH (2015) IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway 1. Dig Dis Sci DOI: 10.1007/s10620-014-3463-1 [published ahead of print].
160. Zhang B, Angelidou A, Alysandratos KD, Vasiadi M, Francis K, Asadi S, Theoharides A, Sideri K, Lykouras L, Kalogeromitros D, et al. (2010) Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J Neuroinflammation 7:80.
161. Zhang B, Alysandratos KD, Angelidou A, Asadi S, Sismanopoulos N, Delivanis DA, Weng Z, Miniati A, Vasiadi M, Katsarou-Katsari A, et al. (2011a) Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol 127: 1522-1531, e8.
162. Zhang L, Lu R, Zhao G, Pflugfelder SC, and Li DQ (2011b) TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol 43:1383-1391.
163. Zhang F, Tossberg JT, Spurlock CF, Yao SY, Aune TM, and Sriram S (2014) Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis. Ann Clin Transl Neurol 1:307-318.
164. Zhao W and Hu Z (2010) The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol 7:260-262.